Mills Richard P, Budenz Donald L, Lee Paul P, Noecker Robert J, Walt John G, Siegartel Lisa R, Evans Stacy J, Doyle John J
University of Washington, Seattle, Washington, USA.
Am J Ophthalmol. 2006 Jan;141(1):24-30. doi: 10.1016/j.ajo.2005.07.044.
To provide a reliable, comprehensive staging system to assess glaucoma stage in the absence of an universally accepted glaucoma staging system (GSS) on the basis of visual field results.
Literature review and GSS adaptation.
After a review of published GSSs was conducted, the Bascom Palmer (Hodapp-Anderson-Parrish) GSS was selected as an appropriate platform for a retrospective GSS on the basis of visual fields. The system was modified by a panel of glaucoma specialists, and additional modifications were made after pilot testing to cover the full range of disease progression, from preglaucoma diagnosis to complete blindness; the ordered stages reflect the typical progression of glaucoma.
The GSS is comprised of six ordered stages and is on the basis of the Humphrey visual field. The completed GSS was validated by reviewing patient charts from 12 US glaucoma centers.
The GSS allows accurate staging of 100% of glaucoma on the basis of visual fields and other data, enabling evaluation of disease progression and resource utilization at various glaucoma stages. Additionally, treatment costs may be assigned to determine cost-effectiveness of treatment. Research utilizing the GSS has found that cost of care increases with increasing disease severity. The GSS may be used as the basis for creating treatment guidelines, which have the potential to delay glaucoma progression and lower treatment costs.
在缺乏基于视野结果的普遍接受的青光眼分期系统(GSS)的情况下,提供一种可靠、全面的分期系统来评估青光眼分期。
文献综述和GSS改编。
在对已发表的GSS进行综述后,基于视野选择巴斯科姆·帕尔默(霍达普 - 安德森 - 帕里什)GSS作为回顾性GSS的合适平台。该系统由一组青光眼专家进行修改,并在试点测试后进行了额外修改,以涵盖从青光眼前期诊断到完全失明的整个疾病进展范围;有序的阶段反映了青光眼的典型进展。
GSS由六个有序阶段组成,基于汉弗莱视野。通过回顾来自12个美国青光眼中心的患者病历对完成的GSS进行了验证。
GSS能够根据视野和其他数据对100%的青光眼进行准确分期,从而能够评估不同青光眼阶段的疾病进展和资源利用情况。此外,可以确定治疗成本以评估治疗的成本效益。利用GSS的研究发现,护理成本随着疾病严重程度的增加而增加。GSS可作为制定治疗指南的基础,这有可能延缓青光眼进展并降低治疗成本。